I just read
SIRT1 stimulation by polyphenols is affected by their stability and metabolismBy de Boer et al
I found this quote and was wondering if somebody could help explain it a little more.
Both ECg and EGCg stimulated the activity of recombinant
SIRT1, while EC and EGC were not able to stimulate SIRT1.
Thus the attached gallic acid group seems to be necessary for a
stimulating activity of catechins. An advantage of this
gallolyation of the polyphenolic backbone is that these
polyphenols are hardly conjugated to glucuronides and sulfates
in the human body. Therefore, EGCg is present in human
plasma for 77–90% in its free form (Manach et al., 2005),
whereas other polyphenols, like resveratrol, myricetin and
quercetin, are conjugated to glucuronides and sulfates. Tissues,
other than gastro-intestinal tract tissues, are also mainly
exposed to conjugates of resveratrol (Wenzel et al., 2005) and
quercetin (de Boer et al., 2005), while EGCg was found in
tissues in its unconjugated form (Meng et al., 2002). This may
have a significant impact on the bioactivity of EGCg in the
human body.
From what I understand resveratrol, myricetin and quercetin form a peroxide during the conversion to its breakdown products. What I'm confused about is it the H202 or the breakdown products that could be potentially inhibiting the SIRT1 gene???
What I found interesting is that EGCg is REALLY bio-available seen at 77-90% in the plasma. However, they noticed that if you don't add Vit-C it could inhibit SIRT1. However, if you find over half of the (77-90%) in the plasma is that a wining percentage?
After doing some research I found this that seems to contradict the bio-availabilty of EGCG.
Piperine Enhances bioavailability(–)-Epigallocatechin-3-gallate (EGCG), from green tea (Camellia sinensis), has demonstrated chemopreventive activity in animal models of carcinogenesis. Previously, we reported the bioavailability of EGCG in rats (1.6%) and mice (26.5%)
Maybe humans just absorb it more???
Interesting fact about piperine
Piperine appeared to increase EGCG bioavailability by inhibiting glucuronidation and gastrointestinal transit.
Small intestinal EGCG levels in CF-1 mice following treatment with EGCG alone had a Cmax = 37.50 ± 22.50 nmol/g at 60 min that then decreased to 5.14 ± 1.65 nmol/g at 90 min; however, cotreatment with piperine resulted in a Cmax = 31.60 ± 15.08 nmol/g at 90 min, and levels were maintained above 20 nmol/g until 180 min. This resulted in a significant increase in the small intestine EGCG AUC (4621.80 ± 1958.72 vs. 1686.50 ± 757.07 (nmol/g·min)).
From another paper (Human bioavailability)
In regard to the EGCG bioavailability, pharmacokinetic studies in humans indicate the peak plasma concentration of EGCG is ~0.2 to 1 µg/mL (38, 39),
Bio-bioavailability of EGCG
Edited by hedgehog_info, 21 December 2007 - 03:54 AM.